This article is more than 5 years old. Information may no longer be current.

NovaBay reports lower net loss in 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NovaBay Pharmaceuticals reported a 2014 net loss of $15.2 million, or $0.31 per share, compared with $16 million, or $0.42 per share, in 2013, according to a press release.

The lower net loss in 2014 was attributed to decreased spending on research and development activities. Sales revenue was $684,000 in 2014 compared with $223,000 in 2013.

License, collaboration, distribution and other revenue was $370,000 in 2014 compared with $3.3 million in 2013. Research and development expenses were $9.5 million in 2014 compared with $12.5 million in 2013.